Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications

Application Number	Priority Date	Filing Date
US201361782531P	2013-03-14	2013-03-14
US201361837399P	2013-06-20	2013-06-20
US201361904579P	2013-11-15	2013-11-15
US201361912777P	2013-12-06	2013-12-06
US201461942367P	2014-02-20	2014-02-20

Publication Number	Publication Date
SG10201912286TAtrue SG10201912286TA (en)	2020-02-27

Family

ID=50678278

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201912286TASG10201912286TA (en)	2013-03-14	2014-03-13	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SG11201507400SASG11201507400SA (en)	2013-03-14	2014-03-13	Complement component c5 irna compositions and methods of use thereof
SG10201700239UASG10201700239UA (en)	2013-03-14	2014-03-13	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG11201507400SASG11201507400SA (en)	2013-03-14	2014-03-13	Complement component c5 irna compositions and methods of use thereof
SG10201700239UASG10201700239UA (en)	2013-03-14	2014-03-13	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Country Status (35)

Country	Link
US (7)	US9249415B2 (en)
EP (2)	EP3312281A3 (en)
JP (4)	JP6524060B2 (en)
KR (4)	KR102605775B1 (en)
CN (3)	CN105324485B (en)
AU (3)	AU2014244116B9 (en)
BR (1)	BR112015022876B1 (en)
CA (2)	CA3216595A1 (en)
CL (4)	CL2015002710A1 (en)
CR (1)	CR20150493A (en)
CY (1)	CY1120289T1 (en)
DK (1)	DK2970974T3 (en)
DO (1)	DOP2015000234A (en)
EA (1)	EA201591707A1 (en)
ES (1)	ES2649490T3 (en)
GT (1)	GT201500293A (en)
HK (1)	HK1252501A1 (en)
HR (1)	HRP20171813T1 (en)
HU (1)	HUE034987T2 (en)
IL (3)	IL288931B2 (en)
LT (1)	LT2970974T (en)
ME (1)	ME03043B (en)
MX (2)	MX366660B (en)
MY (1)	MY201504A (en)
NZ (1)	NZ712336A (en)
PE (2)	PE20160046A1 (en)
PL (1)	PL2970974T3 (en)
PT (1)	PT2970974T (en)
RS (1)	RS56663B1 (en)
SG (3)	SG10201912286TA (en)
SI (1)	SI2970974T1 (en)
SM (1)	SMT201700552T1 (en)
TW (5)	TWI660731B (en)
UY (2)	UY35442A (en)
WO (1)	WO2014160129A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
EP2780454A2 (en)	2011-11-18	2014-09-24	Alnylam Pharmaceuticals, Inc.	Modified rnai agents
SG10201912286TA (en)	2013-03-14	2020-02-27	Alnylam Pharmaceuticals Inc	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2014160958A1 (en)	2013-03-29	2014-10-02	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR102369736B1 (en)	2014-05-01	2022-03-02	아이오니스 파마수티컬즈, 인코포레이티드	Compositions and methods for modulating complement factor b expression
IL316808A (en)	2014-08-20	2025-01-01	Alnylam Pharmaceuticals Inc	Modified double-stranded rna agents and uses thereof
EP3191591A1 (en)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016044419A1 (en)*	2014-09-16	2016-03-24	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
JOP20200115A1 (en)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
US10036017B2 (en)*	2015-02-17	2018-07-31	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
JP6944375B2 (en)*	2015-03-31	2021-10-06	アレクシオンファーマシューティカルズ，インコーポレイテッド	Identification and treatment of a subpopulation of patients with paroxysmal nocturnal hemoglobinuria (PNH)
KR20250107273A (en)*	2015-05-06	2025-07-11	알닐람 파마슈티칼스 인코포레이티드	Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3307316A1 (en)*	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
JP6715325B2 (en)*	2015-06-26	2020-07-01	スーチョウリボライフサイエンスカンパニー、リミテッドＳｕｚｈｏｕＲｉｂｏＬｉｆｅＳｃｉｅｎｃｅＣｏ．，Ｌｔｄ．	siRNA, pharmaceutical composition and conjugate containing siRNA, and applications thereof
JP6666002B2 (en)*	2015-10-07	2020-03-13	国立大学法人京都大学	Composition for preventing or treating TDP-43 proteinenopathy
US20190256845A1 (en)*	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
US20190351071A1 (en)*	2016-11-11	2019-11-21	Dnalite Therapeutics, Inc.	Structures and methods for gene therapy
AU2017368050A1 (en)	2016-11-29	2019-06-20	Puretech Lyt, Inc.	Exosomes for delivery of therapeutic agents
IL268327B2 (en)*	2017-01-31	2025-09-01	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2018249310A1 (en)*	2017-04-03	2019-10-17	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of C5a activity
US10376595B2 (en)	2017-04-03	2019-08-13	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of C5a activity
EP3642230A1 (en)*	2017-06-23	2020-04-29	InflaRx GmbH	Treatment of inflammatory diseases with inhibitors of c5a activity
JP7337044B2 (en)	2017-07-13	2023-09-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	Method for inhibiting HAO1 (hydroxy acid oxidase 1 (glycolic acid oxidase)) gene expression
WO2019089922A1 (en)	2017-11-01	2019-05-09	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
JP7365052B2 (en)	2017-12-01	2023-10-19	スーチョウリボライフサイエンスカンパニー、リミテッド	Nucleic acids, compositions and complexes containing the nucleic acids, and preparation methods and uses
US11414661B2 (en)	2017-12-01	2022-08-16	Suzhou Ribo Life Science Co., Ltd.	Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2019105435A1 (en)	2017-12-01	2019-06-06	苏州瑞博生物技术有限公司	Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
KR20250107294A (en)	2017-12-01	2025-07-11	쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드	Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11492620B2 (en)	2017-12-01	2022-11-08	Suzhou Ribo Life Science Co., Ltd.	Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
HRP20250408T1 (en)	2017-12-29	2025-06-06	Suzhou Ribo Life Science Co., Ltd.	Conjugates and preparation and use thereof
GB201800620D0 (en)	2018-01-15	2018-02-28	Univ Manchester	C3b Binding Polypeptide
EP3597222A1 (en)	2018-07-16	2020-01-22	Easemedcontrol R & D GmbH & Co KG	Treatment and diagnosis of unresolved inflammatory diseases
JP2021533800A (en)	2018-08-21	2021-12-09	スーチョウリボライフサイエンスカンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd.	Nucleic acid, drug compositions and complexes containing the nucleic acid, and their use
WO2020060987A1 (en)*	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use
JP7376952B2 (en)	2018-09-30	2023-11-09	スーチョウリボライフサイエンスカンパニー、リミテッド	siRNA complex and its preparation method and use
US10526603B1 (en)	2018-10-26	2020-01-07	Eisai R&D Management Co., Ltd.	Double-stranded ribonucleic acid capable of suppressing expression of complement C5
US11510939B1 (en)	2019-04-19	2022-11-29	Apellis Pharmaceuticals, Inc.	RNAs for complement inhibition
EP3978029A4 (en)*	2019-05-24	2023-07-19	Suzhou Ribo Life Science Co., Ltd.	Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
EP4013784A1 (en)	2019-08-16	2022-06-22	Regeneron Pharmaceuticals, Inc.	High concentration anti-c5 formulations
MX2022002397A (en)*	2019-08-27	2022-08-25	Silence Therapeutics Gmbh	Nucleic acids for inhibiting expression of c3 in a cell.
KR20220084399A (en)	2019-10-22	2022-06-21	알닐람 파마슈티칼스 인코포레이티드	Complement component C3 iRNA compositions and methods of use thereof
CN115052889A (en)	2019-10-25	2022-09-13	瑞泽恩制药公司	Dosing regimens for treating or preventing C5 related diseases
CN110865182B (en)*	2019-11-19	2023-06-27	东莞市东阳光诊断产品有限公司	Blocking agent and application thereof in immunodetection
CN111041025B (en)	2019-12-17	2021-06-18	深圳市瑞吉生物科技有限公司	mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof
CN111134115B (en)*	2019-12-24	2021-08-10	东华大学	Pesticide retention agent and preparation method thereof
WO2021132462A1 (en)	2019-12-26	2021-07-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement c5
JP6918197B2 (en)*	2019-12-26	2021-08-11	エーザイ・アール・アンド・ディー・マネジメント株式会社	Pharmaceutical composition containing lipid complex and pharmaceutical composition containing lipid nanoparticles
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022021136A2 (en)	2020-04-30	2022-11-29	Alnylam Pharmaceuticals Inc	COMPLEMENT FACTOR B IRNA COMPOSITIONS (CFB) AND METHODS OF USE THEREOF
US20230323357A1 (en)*	2020-06-09	2023-10-12	Alnylam Pharmaceuticals, Inc.	TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN111744019B (en)	2020-07-01	2023-08-04	深圳瑞吉生物科技有限公司	Mannose-based mRNA targeted delivery system and application thereof
US20230332147A1 (en)*	2020-09-09	2023-10-19	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing growth factor receptor bound protein 10 (grb10) or growth factor receptor bound protein 14 (grb14) in the liver
EP4401742A2 (en)	2021-09-17	2024-07-24	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
US11957178B2 (en)	2021-11-15	2024-04-16	Apackaging Group Llc	Aerosol actuator
WO2023088455A1 (en)*	2021-11-22	2023-05-25	苏州瑞博生物技术股份有限公司	Nucleic acid, pharmaceutical composition containing same, sirna conjugate, preparation method, and use
EP4454665A1 (en)*	2021-12-22	2024-10-30	NA Vaccine Institute	Composition for preventing or treating ischemia-reperfusion injury and use thereof
CN117264950A (en)*	2022-07-07	2023-12-22	北京福元医药股份有限公司	Double-stranded ribonucleic acid for inhibiting C5 gene expression, and modification, conjugate and application thereof
US12180274B2 (en)	2023-05-26	2024-12-31	Inflarx Gmbh	Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
CN119816596A (en)*	2023-05-26	2025-04-11	石药集团中奇制药技术（石家庄）有限公司	A dsRNA molecule for inhibiting C5 gene expression and its application
CN118773195A (en)*	2023-06-16	2024-10-15	施能康医药科技(苏州)有限公司	Nucleic acids targeting complement component 5 and uses thereof
TW202510894A (en)*	2023-08-04	2025-03-16	美商艾拉倫製藥公司	Aminoadipate-semialdehyde synthase (aass) irna compositions and methods of use thereof
WO2025143001A1 (en)*	2023-12-27	2025-07-03	東亞合成株式会社	Novel double-stranded rna based on c5 rna sequence, and use thereof
WO2025148349A1 (en)*	2024-01-08	2025-07-17	润佳(上海)医药技术有限公司	Dsrna for inhibiting c5 gene expression and use thereof

Family Cites Families (269)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US564562A (en)		1896-07-21		Joseph p
US1861608A (en)	1929-12-21	1932-06-07	Emerson Electric Mfg Co	Fan and means for directing the air current therethrough
US1861108A (en)	1930-01-24	1932-05-31	Eugene O Brace	Integral clutch and transmission control
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3974808A (en)	1975-07-02	1976-08-17	Ford Motor Company	Air intake duct assembly
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4476301A (en)	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (en)	1982-08-09	1984-02-14	Wakunaga Seiyaku Kk	Oligonucleotide derivative and its preparation
US4708708A (en)	1982-12-06	1987-11-24	International Paper Company	Method and apparatus for skiving and hemming
FR2540122B1 (en)	1983-01-27	1985-11-29	Centre Nat Rech Scient	NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4605735A (en)	1983-02-14	1986-08-12	Wakunaga Seiyaku Kabushiki Kaisha	Oligonucleotide derivatives
US4948882A (en)	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en)	1983-03-10	1989-04-25	Julian Gordon	Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en)	1983-09-01	1986-05-06	The Johns Hopkins University	Linkage of proteins to nucleic acids
US5118802A (en)	1983-12-20	1992-06-02	California Institute Of Technology	DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en)	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en)	1984-07-19	1989-02-17	Centre Nat Rech Scient	NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5258506A (en)	1984-10-16	1993-11-02	Chiron Corporation	Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en)	1984-10-16	1995-07-04	Chiron Corporation	Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
US4828979A (en)	1984-11-08	1989-05-09	Life Technologies, Inc.	Nucleotide analogs for nucleic acid labeling and detection
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2575751B1 (en)	1985-01-08	1987-04-03	Pasteur Institut	NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en)	1989-12-20	1995-04-11	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4762779A (en)	1985-06-13	1988-08-09	Amgen Inc.	Compositions and methods for functionalizing nucleic acids
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5317098A (en)	1986-03-17	1994-05-31	Hiroaki Shizuya	Non-radioisotope tagging of fragments
JPS638396A (en)	1986-06-30	1988-01-14	Wakunaga Pharmaceut Co Ltd	Poly-labeled oligonucleotide derivative
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en)	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
EP0366685B1 (en)	1987-06-24	1994-10-19	Howard Florey Institute Of Experimental Physiology And Medicine	Nucleoside derivatives
US5585481A (en)	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en)	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
US5525465A (en)	1987-10-28	1996-06-11	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (en)	1987-11-12	1989-05-24	Max Planck Gesellschaft	MODIFIED OLIGONUCLEOTIDS
FR2623508B1 (en)	1987-11-20	1990-04-20	Commissariat Energie Atomique	BASIC PROTEIN NAMED PHOSPHOLIPASE A2 ISOLATED FROM SNAP VENOM OF THE ELAPID FAMILY AND ITS AMINO ACID SEQUENCE, DERIVATIVES AND FRAGMENTS OF THE SAME, PROCESS FOR OBTAINING THERAPEUTIC COMPOSITIONS, AND DIAGNOSTIC AGENTS CONTAINING SAME AND / OR ITS FRAGMENTS
US5082830A (en)	1988-02-26	1992-01-21	Enzo Biochem, Inc.	End labeled nucleotide probe
JPH03503894A (en)	1988-03-25	1991-08-29	ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション	Oligonucleotide N-alkylphosphoramidate
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5262536A (en)	1988-09-15	1993-11-16	E. I. Du Pont De Nemours And Company	Reagents for the preparation of 5'-tagged oligonucleotides
US5512439A (en)	1988-11-21	1996-04-30	Dynal As	Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en)	1989-03-06	1997-02-04	Board Of Regents, University Of Tx	Texaphyrin metal complexes having improved functionalization
US5457183A (en)	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
FR2645866B1 (en)	1989-04-17	1991-07-05	Centre Nat Rech Scient	NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5391723A (en)	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5744101A (en)	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5032401A (en)	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
NL8901881A (en)	1989-07-20	1991-02-18	Rockwool Grodan Bv	Drainage coupling element.
US5451463A (en)	1989-08-28	1995-09-19	Clontech Laboratories, Inc.	Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US5254469A (en)	1989-09-12	1993-10-19	Eastman Kodak Company	Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
DK0497875T3 (en)	1989-10-24	2000-07-03	Gilead Sciences Inc	2'-modified oligonucleotides
US5292873A (en)	1989-11-29	1994-03-08	The Research Foundation Of State University Of New York	Nucleic acids labeled with naphthoquinone probe
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
US5486603A (en)	1990-01-08	1996-01-23	Gilead Sciences, Inc.	Oligonucleotide having enhanced binding affinity
US7037646B1 (en)	1990-01-11	2006-05-02	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US5578718A (en)	1990-01-11	1996-11-26	Isis Pharmaceuticals, Inc.	Thiol-derivatized nucleosides
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US6783931B1 (en)	1990-01-11	2004-08-31	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5214136A (en)	1990-02-20	1993-05-25	Gilead Sciences, Inc.	Anthraquinone-derivatives oligonucleotides
WO1991013080A1 (en)	1990-02-20	1991-09-05	Gilead Sciences, Inc.	Pseudonucleosides and pseudonucleotides and their polymers
US5321131A (en)	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (en)	1990-05-11	1998-11-26	Microprobe Corp., Bothell, Wash.	Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US5981276A (en)	1990-06-20	1999-11-09	Dana-Farber Cancer Institute	Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5688941A (en)	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5138045A (en)	1990-07-27	1992-08-11	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5218105A (en)	1990-07-27	1993-06-08	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
EP0544824B1 (en)	1990-07-27	1997-06-11	Isis Pharmaceuticals, Inc.	Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
ATE131827T1 (en)	1990-08-03	1996-01-15	Sterling Winthrop Inc	COMPOUNDS AND METHODS FOR SUPPRESSING GENE EXPRESSION
US5245022A (en)	1990-08-03	1993-09-14	Sterling Drug, Inc.	Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en)	1990-08-28	1996-04-30	Reed; Michael W.	Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en)	1990-09-12	1993-05-25	Sterling Winthrop Inc.	Process of linking nucleosides with a siloxane bridge
US5561225A (en)	1990-09-19	1996-10-01	Southern Research Institute	Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
AU662298B2 (en)	1990-09-20	1995-08-31	Gilead Sciences, Inc.	Modified internucleoside linkages
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2095212A1 (en)	1990-11-08	1992-05-09	Sudhir Agrawal	Incorporation of multiple reporter groups on synthetic oligonucleotides
GB9100304D0 (en)	1991-01-08	1991-02-20	Ici Plc	Compound
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US5539082A (en)	1993-04-26	1996-07-23	Nielsen; Peter E.	Peptide nucleic acids
US5714331A (en)	1991-05-24	1998-02-03	Buchardt, Deceased; Ole	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en)	1993-11-22	1998-02-17	Buchardt, Deceased; Ole	Peptide nucleic acids having amino acid side chains
US5371241A (en)	1991-07-19	1994-12-06	Pharmacia P-L Biochemicals Inc.	Fluorescein labelled phosphoramidites
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
EP0538194B1 (en)	1991-10-17	1997-06-04	Novartis AG	Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
ATE241426T1 (en)	1991-11-22	2003-06-15	Affymetrix Inc A Delaware Corp	METHOD FOR PRODUCING POLYMER ARRAYS
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
US6277603B1 (en)	1991-12-24	2001-08-21	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
AU669353B2 (en)	1991-12-24	1996-06-06	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5595726A (en)	1992-01-21	1997-01-21	Pharmacyclics, Inc.	Chromophore probe for detection of nucleic acid
US5565552A (en)	1992-01-21	1996-10-15	Pharmacyclics, Inc.	Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (en)	1992-02-05	1994-10-28	Centre Nat Rech Scient	OLIGOTHIONUCLEOTIDES.
DE4203923A1 (en)	1992-02-11	1993-08-12	Henkel Kgaa	METHOD FOR PRODUCING POLYCARBOXYLATES ON A POLYSACCHARIDE BASE
US5633360A (en)	1992-04-14	1997-05-27	Gilead Sciences, Inc.	Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en)	1992-06-01	1995-07-18	Gilead Sciences, Inc.	Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5587308A (en)	1992-06-02	1996-12-24	The United States Of America As Represented By The Department Of Health & Human Services	Modified adeno-associated virus vector capable of expression from a novel promoter
WO1993025673A1 (en)	1992-06-04	1993-12-23	The Regents Of The University Of California	In vivo gene therapy with intron-free sequence of interest
AU4541093A (en)	1992-06-18	1994-01-24	Genpharm International, Inc.	Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
EP0577558A2 (en)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5272250A (en)	1992-07-10	1993-12-21	Spielvogel Bernard F	Boronated phosphoramidate compounds
EP0654077A4 (en)	1992-07-17	1996-03-13	Ribozyme Pharm Inc	Method and reagent for treatment of animal diseases.
US6346614B1 (en)	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
US5783701A (en)	1992-09-08	1998-07-21	Vertex Pharmaceuticals, Incorporated	Sulfonamide inhibitors of aspartyl protease
JPH08503855A (en)	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	Gene therapy for cystic fibrosis
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
DE69422163T2 (en)	1993-02-19	2000-06-15	Nippon Shinyaku Co., Ltd.	GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
DE69404289T2 (en)	1993-03-30	1998-02-19	Sanofi Sa	ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
WO1994022891A1 (en)	1993-03-31	1994-10-13	Sterling Winthrop Inc.	Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (en)	1993-04-10	1994-10-13	Degussa	Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US6191105B1 (en)	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5955591A (en)	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
US6294664B1 (en)	1993-07-29	2001-09-25	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
CA2176256A1 (en)	1993-11-16	1995-05-26	Lyle John Arnold, Jr.	Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US6054299A (en)	1994-04-29	2000-04-25	Conrad; Charles A.	Stem-loop cloning vector and method
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
US5543152A (en)	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5597696A (en)	1994-07-18	1997-01-28	Becton Dickinson And Company	Covalent cyanine dye oligonucleotide conjugates
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en)	1994-08-25	1996-12-03	Chiron Corporation	N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5556752A (en)	1994-10-24	1996-09-17	Affymetrix, Inc.	Surface-bound, unimolecular, double-stranded DNA
US6608035B1 (en)	1994-10-25	2003-08-19	Hybridon, Inc.	Method of down-regulating gene expression
US5665557A (en)	1994-11-14	1997-09-09	Systemix, Inc.	Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
JP3269301B2 (en)	1994-12-28	2002-03-25	豊田合成株式会社	Rubber compound for glass run
JPH10512894A (en)	1995-03-06	1998-12-08	アイシス・ファーマシューティカルス・インコーポレーテッド	Improved method for the synthesis of 2'-O-substituted pyrimidines and their oligomeric compounds
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH11508231A (en)	1995-05-26	1999-07-21	ソマティックスセラピーコーポレイション	Delivery vehicles containing stable lipid / nucleic acid complexes
US5545531A (en)	1995-06-07	1996-08-13	Affymax Technologies N.V.	Methods for making a device for concurrently processing multiple biological chip assays
US5976567A (en)	1995-06-07	1999-11-02	Inex Pharmaceuticals Corp.	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7422902B1 (en)	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en)	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US5858397A (en)	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
CA2234931C (en)	1995-10-16	2010-01-19	Dana-Farber Cancer Institute	Novel expression vectors and methods of use
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US5994316A (en)	1996-02-21	1999-11-30	The Immune Response Corporation	Method of preparing polynucleotide-carrier complexes for delivery to cells
US6444423B1 (en)	1996-06-07	2002-09-03	Molecular Dynamics, Inc.	Nucleosides comprising polydentate ligands
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6034135A (en)	1997-03-06	2000-03-07	Promega Biosciences, Inc.	Dimeric cationic lipids
JP3756313B2 (en)	1997-03-07	2006-03-15	武今西	Novel bicyclonucleosides and oligonucleotide analogues
EP1027033B1 (en)	1997-05-14	2009-07-22	The University Of British Columbia	High efficiency encapsulation of nucleic acids in lipid vesicles
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6320017B1 (en)	1997-12-23	2001-11-20	Inex Pharmaceuticals Corp.	Polyamide oligomers
EE200000386A (en)	1997-12-24	2001-12-17	Vertex Pharmaceuticals Incorporated	Prodrugs of aspartyl protease inhibitors
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US7273933B1 (en)	1998-02-26	2007-09-25	Isis Pharmaceuticals, Inc.	Methods for synthesis of oligonucleotides
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
US6531590B1 (en)	1998-04-24	2003-03-11	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
WO2000003683A2 (en)	1998-07-20	2000-01-27	Inex Pharmaceuticals Corporation	Liposomal encapsulated nucleic acid-complexes
AU6430599A (en)	1998-10-09	2000-05-01	Cytogenix, Inc.	Enzymatic synthesis of ssdna
MXPA01003643A (en)	1998-10-09	2003-07-21	Ingene Inc	PRODUCTION OF ssDNA IN VIVO.
US6465628B1 (en)	1999-02-04	2002-10-15	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
CO5261510A1 (en)	1999-02-12	2003-03-31	Vertex Pharma	ASPARTIL PROTEASA INHIBITORS
EP1156812A4 (en)	1999-02-23	2004-09-29	Isis Pharmaceuticals Inc	Multiparticulate formulation
US7084125B2 (en)	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
US7053207B2 (en)	1999-05-04	2006-05-30	Exiqon A/S	L-ribo-LNA analogues
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
AU2001227965A1 (en)	2000-01-21	2001-07-31	Geron Corporation	2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
IT1318539B1 (en)	2000-05-26	2003-08-27	Italfarmaco Spa	PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY HYDROPHILE SUBSTANCES
AU2001293687A1 (en)	2000-10-04	2002-04-15	Cureon A/S	Improved synthesis of purine locked nucleic acid analogues
WO2003015698A2 (en)	2001-08-13	2003-02-27	University Of Pittsburgh	Application of lipid vehicles and use for drug delivery
WO2004007718A2 (en)	2002-07-10	2004-01-22	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Rna-interference by single-stranded rna molecules
US6878805B2 (en)	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
EP2305812A3 (en)	2002-11-14	2012-06-06	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
ATE555118T1 (en)	2003-08-28	2012-05-15	Takeshi Imanishi	NEW SYNTHETIC NUCLEIC ACIDS OF THE CROSS-LINKED N-O BOND TYPE
JP2007523649A (en)	2004-02-10	2007-08-23	サーナ・セラピューティクス・インコーポレイテッド	Inhibition of gene expression via RNA interference using multifunctional short interfering nucleic acids (multifunctional siNA)
KR20070085113A (en)*	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Polynucleotides causing RNA interference, and gene expression inhibition method using the same
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7740861B2 (en)	2004-06-16	2010-06-22	University Of Massachusetts	Drug delivery product and methods
DK1866414T3 (en)	2005-03-31	2012-04-23	Calando Pharmaceuticals Inc	Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
WO2006126040A1 (en)	2005-05-25	2006-11-30	Rosetta Genomics Ltd.	Bacterial and bacterial associated mirnas and uses thereof
ES2516815T3 (en)	2006-01-27	2014-10-31	Isis Pharmaceuticals, Inc.	Analogs of bicyclic nucleic acids modified at position 6
EP1989307B1 (en)	2006-02-08	2012-08-08	Quark Pharmaceuticals, Inc.	NOVEL TANDEM siRNAS
EP4159220A1 (en)	2006-03-08	2023-04-05	Archemix LLC	Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US8106173B2 (en)	2006-04-07	2012-01-31	Idera Pharmaceuticals, Inc.	Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
CA2927045A1 (en)	2006-10-03	2008-04-10	Muthiah Manoharan	Lipid containing formulations
ATE540118T1 (en)*	2006-10-18	2012-01-15	Isis Pharmaceuticals Inc	ANTISENSE COMPOUNDS
CN101657097A (en)*	2007-03-01	2010-02-24	先进视觉疗法公司	With the inflammation is the treatment of diseases of feature
BRPI0809105A2 (en)	2007-03-22	2019-09-10	Novartis Ag	c5 antigens and use of these
JP5737937B2 (en)	2007-07-09	2015-06-17	イデラファーマシューティカルズインコーポレイテッドＩｄｅｒａＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Stabilized immunomodulatory RNA (SIMRA) compounds
JP5519523B2 (en)*	2007-12-04	2014-06-11	アルニラムファーマスーティカルズインコーポレイテッド	Carbohydrate conjugates as oligonucleotide delivery agents
CA2713379A1 (en)*	2008-01-31	2009-11-05	Alnylam Pharmaceuticals, Inc.	Optimized methods for delivery of dsrna targeting the pcsk9 gene
US8940299B2 (en)*	2008-02-28	2015-01-27	Case Western Reserve University	Method of treating cancer
WO2009111701A2 (en)*	2008-03-06	2009-09-11	Case Western Reserve University	Method of treating t cell mediated disorders
NZ588583A (en)	2008-04-15	2012-08-31	Protiva Biotherapeutics Inc	Novel lipid formulations for nucleic acid delivery
KR101672563B1 (en)*	2008-10-22	2016-11-03	쿠아크 파마수티칼스 인코퍼레이티드	Methods for treating eye disorders
DK2894165T5 (en)	2008-11-10	2024-10-14	Alexion Pharma Inc	Methods and compositions for treating complement-related disorders
JP5875976B2 (en)	2009-06-01	2016-03-02	ヘイロー−バイオアールエヌエーアイセラピューティクス，インコーポレイテッド	Polynucleotides, compositions and methods for their use for multivalent RNA interference
KR102374518B1 (en)	2009-06-10	2022-03-16	알닐람 파마슈티칼스 인코포레이티드	Improved lipid formulation
WO2010148013A2 (en)*	2009-06-15	2010-12-23	Alnylam Pharmaceuticals, Inc.	Lipid formulated dsrna targeting the pcsk9 gene
RU2012102021A (en)	2009-06-23	2013-07-27	Алексион Фармасьютикалз, Инк.	SPECIFIC ANTIBODIES THAT CONTACT PROTEIN PROTEINS
WO2011005861A1 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
DK2470656T3 (en)	2009-08-27	2015-06-22	Idera Pharmaceuticals Inc	COMPOSITION FOR INHIBITING GENEPRESSION AND APPLICATIONS THEREOF
US9290736B2 (en)*	2009-11-04	2016-03-22	Case Western Reserve University	Compositions and methods of treating T cell mediated disorder
WO2011078672A1 (en)*	2009-12-24	2011-06-30	Prosensa Technologies B.V.	Molecule for treating an inflammatory disorder
JP5852021B2 (en)	2010-03-01	2016-02-03	アレクシオンファーマシューティカルズ，インコーポレイテッド	Methods and compositions for treating dogo disease
WO2012177639A2 (en)	2011-06-22	2012-12-27	Alnylam Pharmaceuticals, Inc.	Bioprocessing and bioproduction using avian cell lines
EP2780454A2 (en)*	2011-11-18	2014-09-24	Alnylam Pharmaceuticals, Inc.	Modified rnai agents
SMT202000308T1 (en)*	2011-11-18	2020-07-08	Alnylam Pharmaceuticals Inc	Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
CA2873776A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics Inc.	Compositions and methods for modulating pten expression
SG10201912286TA (en)	2013-03-14	2020-02-27	Alnylam Pharmaceuticals Inc	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2014160958A1 (en)	2013-03-29	2014-10-02	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP3191591A1 (en)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016044419A1 (en)	2014-09-16	2016-03-24	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3307316A1 (en)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
US20190256845A1 (en)	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2020060987A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use

2014
- 2014-03-13SGSG10201912286TApatent/SG10201912286TA/enunknown
- 2014-03-13EPEP17187047.0Apatent/EP3312281A3/enactivePending
- 2014-03-13CACA3216595Apatent/CA3216595A1/enactivePending
- 2014-03-13ESES14722018.0Tpatent/ES2649490T3/enactiveActive
- 2014-03-13CNCN201480027279.0Apatent/CN105324485B/enactiveActive
- 2014-03-13PEPE2015002003Apatent/PE20160046A1/enunknown
- 2014-03-13ILIL288931Apatent/IL288931B2/enunknown
- 2014-03-13KRKR1020217041252Apatent/KR102605775B1/enactiveActive
- 2014-03-13RSRS20171204Apatent/RS56663B1/enunknown
- 2014-03-13EAEA201591707Apatent/EA201591707A1/enunknown
- 2014-03-13HUHUE14722018Apatent/HUE034987T2/enunknown
- 2014-03-13LTLTEP14722018.0Tpatent/LT2970974T/enunknown
- 2014-03-13DKDK14722018.0Tpatent/DK2970974T3/enactive
- 2014-03-13SMSM20170552Tpatent/SMT201700552T1/enunknown
- 2014-03-13NZNZ712336Apatent/NZ712336A/enunknown
- 2014-03-13BRBR112015022876-3Apatent/BR112015022876B1/enactiveIP Right Grant
- 2014-03-13KRKR1020217008410Apatent/KR102342916B1/enactiveActive
- 2014-03-13SGSG11201507400SApatent/SG11201507400SA/enunknown
- 2014-03-13SGSG10201700239UApatent/SG10201700239UA/enunknown
- 2014-03-13EPEP14722018.0Apatent/EP2970974B1/enactiveActive
- 2014-03-13MYMYPI2021002227Apatent/MY201504A/enunknown
- 2014-03-13KRKR1020157028742Apatent/KR102234620B1/enactiveActive
- 2014-03-13MEMEP-2017-268Apatent/ME03043B/enunknown
- 2014-03-13PEPE2020000856Apatent/PE20211393A1/enunknown
- 2014-03-13CNCN202411918047.6Apatent/CN120574828A/enactivePending
- 2014-03-13ILIL317249Apatent/IL317249A/enunknown
- 2014-03-13CACA2904654Apatent/CA2904654C/enactiveActive
- 2014-03-13JPJP2016501986Apatent/JP6524060B2/enactiveActive
- 2014-03-13PTPT147220180Tpatent/PT2970974T/enunknown
- 2014-03-13AUAU2014244116Apatent/AU2014244116B9/enactiveActive
- 2014-03-13SISI201430477Tpatent/SI2970974T1/enunknown
- 2014-03-13KRKR1020237039770Apatent/KR20230162998A/enactivePending
- 2014-03-13MXMX2015012796Apatent/MX366660B/enactiveIP Right Grant
- 2014-03-13WOPCT/US2014/025882patent/WO2014160129A2/enactiveApplication Filing
- 2014-03-13CNCN202111348463.3Apatent/CN114015692B/enactiveActive
- 2014-03-13PLPL14722018Tpatent/PL2970974T3/enunknown
- 2014-03-13HRHRP20171813TTpatent/HRP20171813T1/enunknown
- 2014-03-14TWTW103109407Apatent/TWI660731B/enactive
- 2014-03-14UYUY0001035442Apatent/UY35442A/enactiveIP Right Grant
- 2014-03-14TWTW114110088Apatent/TW202528542A/enunknown
- 2014-03-14TWTW110100604Apatent/TWI808369B/enactive
- 2014-03-14UYUY0001040039Apatent/UY40039A/ennot_activeApplication Discontinuation
- 2014-03-14TWTW108114704Apatent/TWI745684B/enactive
- 2014-03-14TWTW112108125Apatent/TWI881304B/enactive
2015
- 2015-04-29USUS14/699,140patent/US9249415B2/enactiveActive
- 2015-09-14CLCL2015002710Apatent/CL2015002710A1/enunknown
- 2015-09-14MXMX2019008380Apatent/MX2019008380A/enunknown
- 2015-09-14DODO2015000234Apatent/DOP2015000234A/enunknown
- 2015-09-14GTGT201500293Apatent/GT201500293A/enunknown
- 2015-09-16CRCR20150493Apatent/CR20150493A/enunknown
- 2015-12-21USUS14/976,261patent/US9850488B2/enactiveActive
2016
- 2016-04-14CLCL2016000882Apatent/CL2016000882A1/enunknown
- 2016-05-11USUS15/151,568patent/US9701963B2/enactiveActive
2017
- 2017-05-26USUS15/606,224patent/US20170268005A1/ennot_activeAbandoned
- 2017-08-07CLCL2017002014Apatent/CL2017002014A1/enunknown
- 2017-11-23CYCY20171101233Tpatent/CY1120289T1/enunknown
2018
- 2018-09-14HKHK18111810.5Apatent/HK1252501A1/enunknown
2019
- 2019-01-14CLCL2019000107Apatent/CL2019000107A1/enunknown
- 2019-03-25ILIL265594Apatent/IL265594B/enunknown
- 2019-04-26JPJP2019085280Apatent/JP6914292B2/enactiveActive
- 2019-05-07USUS16/404,862patent/US11162098B2/enactiveActive
2020
- 2020-06-22AUAU2020204161Apatent/AU2020204161B2/enactiveActive
2021
- 2021-07-12USUS17/372,710patent/US11873491B2/enactiveActive
- 2021-07-13JPJP2021115540Apatent/JP7404308B2/enactiveActive
2023
- 2023-01-11AUAU2023200132Apatent/AU2023200132B2/enactiveActive
- 2023-12-05USUS18/529,152patent/US20240271136A1/enactivePending
- 2023-12-13JPJP2023210187Apatent/JP7717783B2/enactiveActive

Publication number	Publication date
UY35442A (en)	2014-10-31
IL317249A (en)	2025-01-01
US20170268005A1 (en)	2017-09-21
TW202528542A (en)	2025-07-16
CN105324485A (en)	2016-02-10
IL265594B (en)	2022-01-01
TW201505637A (en)	2015-02-16
US9701963B2 (en)	2017-07-11
EA201591707A1 (en)	2016-03-31
US20150247143A1 (en)	2015-09-03
DOP2015000234A (en)	2015-12-31
HUE034987T2 (en)	2018-05-02
IL265594A (en)	2019-05-30
PE20160046A1 (en)	2016-02-14
BR112015022876A2 (en)	2017-11-07
WO2014160129A3 (en)	2014-12-04
KR20150127243A (en)	2015-11-16
JP2024037871A (en)	2024-03-19
MX2019008380A (en)	2019-09-09
JP2016518331A (en)	2016-06-23
JP7717783B2 (en)	2025-08-04
CA2904654A1 (en)	2014-10-02
AU2023200132A1 (en)	2023-04-13
US20160244763A1 (en)	2016-08-25
PT2970974T (en)	2017-11-29
EP2970974B1 (en)	2017-08-23
ES2649490T3 (en)	2018-01-12
US11162098B2 (en)	2021-11-02
CN105324485B (en)	2021-11-23
AU2014244116A1 (en)	2015-10-01
NZ751385A (en)	2021-05-28
MY201504A (en)	2024-02-27
KR102605775B1 (en)	2023-11-29
CN114015692B (en)	2024-12-31
AU2020204161B2 (en)	2022-10-13
RS56663B1 (en)	2018-03-30
CL2019000107A1 (en)	2020-04-03
CN114015692A (en)	2022-02-08
TW202118875A (en)	2021-05-16
SG11201507400SA (en)	2015-10-29
GT201500293A (en)	2018-12-18
US20160108401A1 (en)	2016-04-21
PL2970974T3 (en)	2018-01-31
KR20210156330A (en)	2021-12-24
WO2014160129A2 (en)	2014-10-02
AU2014244116B9 (en)	2020-08-13
CA3216595A1 (en)	2014-10-02
CY1120289T1 (en)	2019-07-10
MX366660B (en)	2019-07-18
EP3312281A2 (en)	2018-04-25
CR20150493A (en)	2016-03-28
US9249415B2 (en)	2016-02-02
US9850488B2 (en)	2017-12-26
TW201932597A (en)	2019-08-16
US11873491B2 (en)	2024-01-16
KR20230162998A (en)	2023-11-29
IL288931B2 (en)	2025-05-01
AU2014244116B2 (en)	2020-03-26
US20240271136A1 (en)	2024-08-15
EP2970974A2 (en)	2016-01-20
US20200032259A1 (en)	2020-01-30
EP3312281A3 (en)	2018-06-27
JP6524060B2 (en)	2019-06-05
UY40039A (en)	2023-01-31
ME03043B (en)	2018-10-20
TWI808369B (en)	2023-07-11
CA2904654C (en)	2023-12-05
JP6914292B2 (en)	2021-08-04
BR112015022876B1 (en)	2022-03-15
JP2021176868A (en)	2021-11-11
KR20210034124A (en)	2021-03-29
AU2020204161A1 (en)	2020-07-09
CL2016000882A1 (en)	2016-12-09
NZ712336A (en)	2020-03-27
KR102234620B1 (en)	2021-04-05
PE20211393A1 (en)	2021-07-27
SI2970974T1 (en)	2017-12-29
TW202325847A (en)	2023-07-01
HK1221484A1 (en)	2017-06-02
DK2970974T3 (en)	2017-12-04
JP7404308B2 (en)	2023-12-25
SMT201700552T1 (en)	2018-01-11
HRP20171813T1 (en)	2017-12-29
IL288931B1 (en)	2025-01-01
CL2015002710A1 (en)	2016-04-22
TWI745684B (en)	2021-11-11
AU2023200132B2 (en)	2025-07-24
CL2017002014A1 (en)	2018-04-27
JP2019142944A (en)	2019-08-29
IL288931A (en)	2022-02-01
HK1252501A1 (en)	2019-05-31
US20220090068A1 (en)	2022-03-24
TWI881304B (en)	2025-04-21
MX2015012796A (en)	2016-02-03
SG10201700239UA (en)	2017-02-27
KR102342916B1 (en)	2021-12-24
CN120574828A (en)	2025-09-02
LT2970974T (en)	2017-12-11
TWI660731B (en)	2019-06-01

Publication	Publication Date	Title
IL288931A (en)	2022-02-01	Complement component c5 irna compositions and methods of use thereof
IL285780A (en)	2021-09-30	Tmprss6 irna compositions and methods of use thereof
IL284757A (en)	2021-08-31	Serpina1 irna compositions and methods of use thereof
IL282401A (en)	2021-06-30	Complementary component iRNA compositions and methods of using them
IL273205A (en)	2020-04-30	Compositions and methods
GB2520795B (en)	2018-04-11	Compositions and methods
EP2953474A4 (en)	2016-12-28	Compositions and methods
SG11201507158WA (en)	2015-10-29	Stabilized polymer compositions and methods of making same
GB201308072D0 (en)	2013-06-12	Compositions and methods
SG11201505955PA (en)	2015-09-29	Novel polymer compositions and methods of making and using same
GB201305813D0 (en)	2013-05-15	Compositions and methods
IL244537A0 (en)	2016-04-21	Novel delivery compositions and methods of using same
HK40111400A (en)	2025-01-03	Complement component c5 irna compositions and methods of use thereof
GB201322617D0 (en)	2014-02-05	Methods and compositions
GB201312393D0 (en)	2013-08-21	Compositions and Methods
GB201300628D0 (en)	2013-02-27	Compositions comprising 15-OHEPA and methods of using the same

Movatterモバイル変換

SG10201912286TA - COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=50678278

Family Applications (3)

Family Applications After (2)

Country Status (35)

Families Citing this family (66)

Family Cites Families (269)

Also Published As

Similar Documents